$Ocugen (OCGN.US)$
1. U.S. Phase 3 Bridging Study:
OCGN submitted an IND application to FDA on October 27, 2021, and FDA issued a Clinical Hold to OCGN on November 26, 2021. Currently, WE are waiting for the response from OCGN to FDA. The OCGN will receive a full response from the FDA on or after December 26, 2021. FDA will proceed with approval within 30 days of receiving OCGN's response.

$Baosheng Media Group (BAOS.US)$ buy the dip

$T2 Biosystems (TTOO.US)$ I finally gave up on this crap

✅Under $5 stocks
BDR
EXPR
SOS
WORX
XELA
$Blonder Tongue Laboratories (BDR.US)$  $Express (EXPR.US)$  $SOS Ltd (SOS.US)$  $SCWorx (WORX.US)$  $Exela Technologies (XELA.US)$

$Chembio Diagnostics (CEMI.US)$ yes

$Ardelyx (ARDX.US)$ shorts dipping it so they can cover. as long as it stays above 1.45 it will recover to 1.75

$Chembio Diagnostics (CEMI.US)$ If you don't improve 📈, nobody will buy from you anymore.

$BlackBerry (BB.US)$ red sea